Mosapride for Functional Dyspepsia: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

WU Zongying ¹ ,  WANG Yiping ¹ , ZENG Chao ²

1. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041,China 2. The 3rd People’s Hospital of Chengdu city, Chengdu, 610014, China;

Corresponding author：

WANG Yiping, Email: wyiping2002@yahoo.com

Keywords：

Mosapride; Functional dyspepsia; Systematic review; Meta-analysis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To determine the effectiveness and safety of mosapride in patients with functional dyspepsia.
Methods 　Trials were located through electronic searches of the Cochrane Central Register of Controlled Trails (CENTRAL) ( Issue 2, 2006), MEDLINE (1978 to Jun. 2006), EMbase (1978 to Jun.2006), ISI (2000 to Jun.2006), OVID Database (1978 to Jun.2006), Chinese Biological Medicine Database (1978 to Jun.2006), Chinese VIP Database (1994 to Jun.2006) and WANFANG Database ( 1978 to Jun.2006). We also checked the bibliographies of retrieved articles and handsearched four kinds of important journals.
Results 　Total of 18 trials involving 2 929 patients were included in the meta-analyses. These showed: (1) remission rate of global symptoms: Mosapride was not superior to placebo (RR 2.72, 95%CI 0.87 to 8.46), but was superior to metoclopramide (RR 1.66, 95%CI 0.82 to 3.35) and domperidone (RR 1.23, 95%CI 1.12 to 1.34); (2) remission rate of individual symptoms: 1) upper abdominal flatulence: Mosapride was superior to domperidone (RR 1.35, 95%CI 1.14 to 1.60), but was not superior to cisapride (RR 0.95, 95%CI 0.78 to 1.15); 2) postprandial fullness: Mosapride was superior to domperidone (RR 2.72, 95%CI 2.02 to 3.66), but was not superior to cisapride (RR 0.99, 95%CI 0.82 to 1.18); 3) upper abdominal pain: Mosapride was superior to domperidone (RR 1.27, 95%CI 1.07 to1.49), but was not superior to cisapride (RR 0.94, 95%CI 0.75 to 1.17); 4) early saciety: Mosapride was superior to domperidone (RR 1.42, 95%CI 1.15 to 1.76), but was not superior to cisapride (RR 0.98, 95%CI 0.82 to 1.17); 5) nausea: Mosapride was not superior to cisapride (RR 1.07, 95%CI 0.82 to 1.39) and domperidone (RR 1.12 ,95%CI 0.97 to 1.28); 6) vomitting: Mosapride was not superior to cisapride (P=0.80) and domperidone (RR 1.02, 95%CI 0.87 to 1.18); 7) eructation: Mosapride was superior to domperidone (RR 1.41, 95%CI 1.17 to 1.70), but was not superior to cisapride (RR 0.85, 95%CI 0.68 to 1.05); 8) anorexia: Mosapride was superior to domperidone (RR 1.22, 95%CI 1.20 to 1.44), but was not superior to cisapride (RR0.88, 95%CI 0.64 to 1.19); 9) sour regurgitation: Mosapride was not superior to domperidone (P=0.64) and cisapride (P=0.32); 10) heartburn: Mosapride was not superior to domperidone (RR 0.97, 95%CI 0.96 to 1.10) and cisapride (RR 1.05, 95%CI 0.90 to 1.21); 11) upper abdominal discomfort: Mosapride was not superior to cisapride (P =0.64); (3) adverse event rate: Mosapride had a good safety profile.
Conclusions 　The limited current evidence shows that, mosapride is not superior to placebo in relieving global symptoms, but is superior to domperidone in relieving upper abdominal flatulence, postprandial fullness, upper abdominal pain, early saciety, erutation and anorexia. Mosapride has a good safety profile.

Citation： WU Zongying,WANG Yiping,ZENG Chao. Mosapride for Functional Dyspepsia: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2006, 06(11): 790-803. doi: Copy

1.	覃业宏. 莫沙必利治疗功能性消化不良的临床观察. 现代医药卫生, 2004; 20(11): 968~969.
2.	许建明, 胡乃中, 谢惠君, 等. 枸橼酸莫沙必利片治疗功能性消化不良的随机对照双盲临床试验评价. 基础医学与临床, 2001; 21(增刊): 54.
3.	达四平, 赵晓晏, 李宜辉, 等. 口服莫沙必利治疗功能性消化不良的随机对照试验. 第三军医大学学报, 2001; 23(5): 593~595.
4.	李国恩, 贺聪霞. 贝络纳治疗功能性消化不良的临床观察. 河南大学学报(医学科学版), 2003; 22(1): 40~41.
5.	黄咏东, 苻林梅. 贝络纳治疗功能性消化不良的临床观察. 华西药学杂志, 2001; 16(4): 317.
6.	王振华, 达四平, 龚能平, 等. 莫沙必利治疗功能性消化不良多中心双盲对照研究. 中国新药与临床杂志, 2000; 19(5): 363~366.
7.	赵晓红, 胡建国, 白东莉. 枸橼酸莫沙必利治疗功能性消化不良的临床观察. 宁夏医学院学报, 2003; 25(6):431~432.
8.	马岚清. 莫沙必利和吗叮啉治疗功能性消化不良的疗效和安全性-随机对照试验(未发表). 2004年四川大学学位论文数据库.
9.	陈世耀, 王吉耀, 朱畴文, 等. 莫沙必利治疗功能性消化不良的随机双盲对照研究. 中华流行病学杂志, 2004; 25(2): 165~168.
10.	徐建舫, 吕文, 吴缅. 莫沙必利治疗功能性消化不良28例. 杭州医学高等专科学校学报, 2002; 23(4): 158~159.
11.	李兆申, 邹多武, 许国铭, 等. 枸橼酸莫沙必利片治疗功能性消化不良的临床研究. 第二军医大学学报, 2002; 23(4): 387~390.
12.	傅永平, 陈龙根. 莫沙必利与西沙必利治疗功能性消化不良的疗效观察. 绍兴文理学院学报, 2003; 23(8): 25~27.
13.	冯常炜, 赵影影, 李振峰, 等. 枸橼酸莫沙必利治疗功能性消化不良临床双盲对照研究. 郑州大学学报 (医学版), 2004; 39(6): 1054~1056.
14.	李见春, 安保国, 许崇德, 等. 莫沙必利治疗功能性消化不良. 中国新药与临床杂志, 2001; 20(2): 150~151.
15.	郭焕伟. 莫沙必利治疗非溃疡性消化不良疗效观察. 山东医药, 2003; 43(1): 67.
16.	徐丽姝, 麦韵萍, 张瑛华. 莫沙必利治疗老年人功能性消化不良200例疗效分析. 实用医学杂志, 2004; 20(7): 842~843.
17.	许国铭. 非溃疡性消化不良专题研讨会纪要. 解放军医学杂志, 1992; 17(1): 68.
18.	陈垦, 梁坚, 麦海妍, 等. 莫沙必利治疗功能性消化不良102例. 医药导报, 2003; 22(6): 394~396.
19.	Xu GM. Summary of the symposium on non-ulcer dyspepsia. Medical Journal of Chinese People’s Liberation Army, 1992; 17(1): 68.
20.	Talley NJ, Svanghellini V, Heading KC, et al. Functional gastroduodenal disorders. Gut, 1999; 45(suppl Ⅱ): 37–42.
21.	Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2, 2005.
22.	Chen K, Liang J, Mai HY, et al. Treatment of 102 cases of functional dyspepsia with mosapride. Herald of Medicine, 2003; 22(6): 394–396.
23.	Tan YH. The clinical observation of mosapride for functional dyspepsia. Morden Medicine and Health, 2004; 20(11): 968–969.
24.	Xu JM, Hu NZ, Xie HJ, et al. A randomized controlled double-blind trial of mosapride for functional dyspepsia. Basic Medical Sciences and Clinics, 2001; 21(sup): 54.
25.	Da SP, Zhao XY, Li YH, et al. RCT on the therapautical effect of mospride citrate in functional dyspepsia. Acta Academiae Medicinae Militaris Tertiae, 2001; 23(5): 593–595.
26.	Li GN, He CX. The clinical observation of mosapride for functional dyspepsia. Journal of Henan University (Medical Science), 2003; 22(1): 40–41.
27.	Huang YD, Fu LM. The clinical observation of mosapride for functional dyspepsia. West China Journal of Pharmaceutical Sciences, 2001; 16(4): 317.
28.	Wang ZH, Da SP, Gong NP, et al. Mosapride in treating functional dyspepsia: a multicenter, double-blind study. Chinese Journal of New Drugs and Clinical Remedies, 2000; 19(5): 363–366.
29.	Zhao XH, Hu JG, Bai DL. The clinical study of mosapride citrate for functional dyspepsia. Journal of Ningxia Medical College, 2003; 25(6): 431–432.
30.	Ma LQ. Mosapride and domperidone for functional dyspepsia: a randomized controlled trial (unpublished). 2004 Sichuan University Dissertation Database.
31.	Chen SY, Wang JY, Zhu CW, et al. A randomized controlled multi-center clinical trial on mosapride in the treatment of functional dyspepsia. Chinese Journal of Epidemiology, 2004; 25(2): 165–168.
32.	Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther, 2002; 16: 959–967.
33.	Xu JF, Lv W, Wu M. 28 cases with functional maldigestion treated with mosapride. Journal of Hangzhou Medical College, 2002; 23(4): 158–159.
34.	Li ZS, Zou DW, Xu GM, et al. Effect of mosapride citrate on functional dyspepsia. Academic Journal of Second Military Medical University, 2002; 23(4): 387–390.
35.	Fu YP, Chen LG. Efficacy of mosapride and cisapride for functional dyspepsia. Journal of Shaoxing University, 2003; 23(8): 25–27.
36.	Feng CW, Zhao YY, Li ZF, et al. Double-blind clinical study on mosapride treatment to functional dyspepsia. Journal of Zhengzhou University (Medicine Sciences), 2004; 39(6): 1054–1056.
37.	Li JC, An BG, Xu CD, et al. Mosapride for functional dyspepsia. Chinese Journal of New Drug and Clinical Remedies, 2001; 20(2): 150–151.
38.	Guo HW. The efficacy of mosapride for non-ulcer dyspepsia. Shandong Medical Journal, 2003; 43(1): 67.
39.	Xu LZ, Mai YP, Zhang YH. 200 cases of senile functional dyspepsia treated with mosapride. Journal of Practical Medicine, 2004; 20(7): 842–843.
40.	Dobrilla G, Comberlato M, Steele A, et al. Drug treatment of functional dyspepsia. J Clin Gastroenterol, 1989; 11(2): 169–177.
41.	Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of antiseceretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol, 1998; 26(4): 312–320.
42.	Velhuyzen van Zanten SJO, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol, 1996; 91: 660–671.

1. 覃业宏. 莫沙必利治疗功能性消化不良的临床观察. 现代医药卫生, 2004; 20(11): 968~969.
2. 许建明, 胡乃中, 谢惠君, 等. 枸橼酸莫沙必利片治疗功能性消化不良的随机对照双盲临床试验评价. 基础医学与临床, 2001; 21(增刊): 54.
3. 达四平, 赵晓晏, 李宜辉, 等. 口服莫沙必利治疗功能性消化不良的随机对照试验. 第三军医大学学报, 2001; 23(5): 593~595.
4. 李国恩, 贺聪霞. 贝络纳治疗功能性消化不良的临床观察. 河南大学学报(医学科学版), 2003; 22(1): 40~41.
5. 黄咏东, 苻林梅. 贝络纳治疗功能性消化不良的临床观察. 华西药学杂志, 2001; 16(4): 317.
6. 王振华, 达四平, 龚能平, 等. 莫沙必利治疗功能性消化不良多中心双盲对照研究. 中国新药与临床杂志, 2000; 19(5): 363~366.
7. 赵晓红, 胡建国, 白东莉. 枸橼酸莫沙必利治疗功能性消化不良的临床观察. 宁夏医学院学报, 2003; 25(6):431~432.
8. 马岚清. 莫沙必利和吗叮啉治疗功能性消化不良的疗效和安全性-随机对照试验(未发表). 2004年四川大学学位论文数据库.
9. 陈世耀, 王吉耀, 朱畴文, 等. 莫沙必利治疗功能性消化不良的随机双盲对照研究. 中华流行病学杂志, 2004; 25(2): 165~168.
10. 徐建舫, 吕文, 吴缅. 莫沙必利治疗功能性消化不良28例. 杭州医学高等专科学校学报, 2002; 23(4): 158~159.
11. 李兆申, 邹多武, 许国铭, 等. 枸橼酸莫沙必利片治疗功能性消化不良的临床研究. 第二军医大学学报, 2002; 23(4): 387~390.
12. 傅永平, 陈龙根. 莫沙必利与西沙必利治疗功能性消化不良的疗效观察. 绍兴文理学院学报, 2003; 23(8): 25~27.
13. 冯常炜, 赵影影, 李振峰, 等. 枸橼酸莫沙必利治疗功能性消化不良临床双盲对照研究. 郑州大学学报 (医学版), 2004; 39(6): 1054~1056.
14. 李见春, 安保国, 许崇德, 等. 莫沙必利治疗功能性消化不良. 中国新药与临床杂志, 2001; 20(2): 150~151.
15. 郭焕伟. 莫沙必利治疗非溃疡性消化不良疗效观察. 山东医药, 2003; 43(1): 67.
16. 徐丽姝, 麦韵萍, 张瑛华. 莫沙必利治疗老年人功能性消化不良200例疗效分析. 实用医学杂志, 2004; 20(7): 842~843.
17. 许国铭. 非溃疡性消化不良专题研讨会纪要. 解放军医学杂志, 1992; 17(1): 68.
18. 陈垦, 梁坚, 麦海妍, 等. 莫沙必利治疗功能性消化不良102例. 医药导报, 2003; 22(6): 394~396.
19. Xu GM. Summary of the symposium on non-ulcer dyspepsia. Medical Journal of Chinese People’s Liberation Army, 1992; 17(1): 68.
20. Talley NJ, Svanghellini V, Heading KC, et al. Functional gastroduodenal disorders. Gut, 1999; 45(suppl Ⅱ): 37–42.
21. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2, 2005.
22. Chen K, Liang J, Mai HY, et al. Treatment of 102 cases of functional dyspepsia with mosapride. Herald of Medicine, 2003; 22(6): 394–396.
23. Tan YH. The clinical observation of mosapride for functional dyspepsia. Morden Medicine and Health, 2004; 20(11): 968–969.
24. Xu JM, Hu NZ, Xie HJ, et al. A randomized controlled double-blind trial of mosapride for functional dyspepsia. Basic Medical Sciences and Clinics, 2001; 21(sup): 54.
25. Da SP, Zhao XY, Li YH, et al. RCT on the therapautical effect of mospride citrate in functional dyspepsia. Acta Academiae Medicinae Militaris Tertiae, 2001; 23(5): 593–595.
26. Li GN, He CX. The clinical observation of mosapride for functional dyspepsia. Journal of Henan University (Medical Science), 2003; 22(1): 40–41.
27. Huang YD, Fu LM. The clinical observation of mosapride for functional dyspepsia. West China Journal of Pharmaceutical Sciences, 2001; 16(4): 317.
28. Wang ZH, Da SP, Gong NP, et al. Mosapride in treating functional dyspepsia: a multicenter, double-blind study. Chinese Journal of New Drugs and Clinical Remedies, 2000; 19(5): 363–366.
29. Zhao XH, Hu JG, Bai DL. The clinical study of mosapride citrate for functional dyspepsia. Journal of Ningxia Medical College, 2003; 25(6): 431–432.
30. Ma LQ. Mosapride and domperidone for functional dyspepsia: a randomized controlled trial (unpublished). 2004 Sichuan University Dissertation Database.
31. Chen SY, Wang JY, Zhu CW, et al. A randomized controlled multi-center clinical trial on mosapride in the treatment of functional dyspepsia. Chinese Journal of Epidemiology, 2004; 25(2): 165–168.
32. Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther, 2002; 16: 959–967.
33. Xu JF, Lv W, Wu M. 28 cases with functional maldigestion treated with mosapride. Journal of Hangzhou Medical College, 2002; 23(4): 158–159.
34. Li ZS, Zou DW, Xu GM, et al. Effect of mosapride citrate on functional dyspepsia. Academic Journal of Second Military Medical University, 2002; 23(4): 387–390.
35. Fu YP, Chen LG. Efficacy of mosapride and cisapride for functional dyspepsia. Journal of Shaoxing University, 2003; 23(8): 25–27.
36. Feng CW, Zhao YY, Li ZF, et al. Double-blind clinical study on mosapride treatment to functional dyspepsia. Journal of Zhengzhou University (Medicine Sciences), 2004; 39(6): 1054–1056.
37. Li JC, An BG, Xu CD, et al. Mosapride for functional dyspepsia. Chinese Journal of New Drug and Clinical Remedies, 2001; 20(2): 150–151.
38. Guo HW. The efficacy of mosapride for non-ulcer dyspepsia. Shandong Medical Journal, 2003; 43(1): 67.
39. Xu LZ, Mai YP, Zhang YH. 200 cases of senile functional dyspepsia treated with mosapride. Journal of Practical Medicine, 2004; 20(7): 842–843.
40. Dobrilla G, Comberlato M, Steele A, et al. Drug treatment of functional dyspepsia. J Clin Gastroenterol, 1989; 11(2): 169–177.
41. Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of antiseceretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol, 1998; 26(4): 312–320.
42. Velhuyzen van Zanten SJO, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol, 1996; 91: 660–671.

Chinese Journal of Evidence-Based Medicine

Mosapride for Functional Dyspepsia: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Format

Content